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Plenary paper
Zebrafish screen identifies novel compound with selective toxicity against
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To detect targeted antileukemia agents we
have designed a novel, high-content in vivo
screen using genetically engineered, T-cell
reporting zebrafish. We exploited the devel-
opmental similarities between normal and
malignant T lymphoblasts to screen a small
molecule library for activity against imma-
ture T cells with a simple visual readout in
zebrafish larvae.After screening 26 400 mol-
ecules, we identified Lenaldekar (LDK), a
compound that eliminates immature T cells
in developing zebrafish without affecting
the cell cycle in other cell types. LDK is well
tolerated in vertebrates and induces long-
term remission in adult zebrafish with cMYC-
induced T-cell acute lymphoblastic leuke-
mia (T-ALL). LDK causes dephosphorylation
of members of the PI3 kinase/AKT/mTOR
pathway and delays sensitive cells in late
mitosis. Among human cancers, LDK selec-
tively affects survival of hematopoietic
malignancy lines and primary leukemias,
including therapy-refractory B-ALL and
chronic myelogenous leukemia samples,
and inhibits growth of human T-ALL xeno-
grafts. This work demonstrates the utility of
our method using zebrafish for antineoplas-
tic candidate drug identification and sug-
gests a new approach for targeted leukemia
therapy. Although our efforts focused on
leukemia therapy, this screening approach
has broad implications as it can be trans-
lated to other cancer types involving malig-
nant degeneration of developmentally ar-
rested cells. (Blood. 2012;119(24):5621-5631)
Introduction
The yearly incidence in the US for all leukemia types, including
acute lymphoblastic leukemia (ALL), acute myeloid leukemia
(AML), and chronic myelogenous leukemia (CML), was estimated
at more than 40 000 men and women in 2010, with a yearly death
rate of 50%.1 More than 2000 cases of ALL are diagnosed in US
children every year, making it the most common childhood cancer.2
T-cell ALL (T-ALL) represents approximately 15% and 25% of
pediatric and adult ALL cases, respectively.3 Although leukemia
treatment has become increasingly efficient over the past 50 years,
mortality from ALL is still 20% for children and more than 40% for
adults, and T-ALL has been more difficult to treat than B-cell ALL
(B-ALL).4 Currently, research efforts are devoted to molecular-
based risk stratification of patients and the development of targeted
therapies to limit side effects5-7 and to increase treatment efficacy.
Development of targeted cancer therapies typically requires
knowledge of the molecular target.8 In the absence thereof, an
alternative approach may use a robust readout designed to screen
large numbers of compounds for specific effects9 against the
malignant cell type in question. More than 50% of patients with
T-ALL have deregulated NOTCH1,10 and in a recent study 47%
had mutations in the PI3 kinase/AKT/mTOR (P/A/mT) pathway.11
NOTCH1 signaling requires proteolytic cleavage by -secretase
and other proteases12 to release the intracytoplasmic domain,
providing severalpotential targets for therapeutic intervention.
Targeted treatment approaches for T-ALL using -secretase inhibi-
tors (GSIs), although appearing a priori promising, have been
disappointing,13 possibly through pre-existing or newly acquired
mutations in phosphatase and tensin homolog (PTEN) that render
many T-ALL cell lines AKT-addicted.14 However, others found that
even in the absence of PTEN, primary murine and human T-ALL
samples remain sensitive to NOTCH inhibition.15 Overall, gain-of-
function mutations in the NOTCH1 and P/A/mT pathways are
strongly selected for in human T-ALL. This has raised interest in
clinically useful, nontoxic inhibitors of the P/A/mT pathway13 for
leukemia and other cancers,16 and makes combined treatment
approaches (anti-NOTCH, anti-P/A/mT) attractive.17
Small molecule screens can be carried out in vitro either using
biochemical assays or cell lines. Although often successful in
providing “hits,” these approaches lack the biologic context of an
entire vertebrate organism, and identified active compounds often
fail when applied in vivo because of poor bioavailability or toxicity.
Although mice are an integral component of preclinical drug
development, their use for high-throughput drug screening is
fiscally prohibitive. Small animal models are therefore needed. For
Submitted December 19, 2011; accepted March 11, 2012. Prepublished online as
Blood First Edition paper, April 9, 2012; DOI 10.1182/blood-2011-12-398818.
*S.R., W.L.H., and D.J. contributed equally to this work.
There is an Inside Blood commentary on this article in this issue.
The online version of this article contains a data supplement.
The publication costs of this article were defrayed in part by page charge
payment. Therefore, and solely to indicate this fact, this article is hereby
marked ‘‘advertisement’’ in accordance with 18 USC section 1734.
© 2012 by The American Society of Hematology
5621BLOOD, 14 JUNE 2012  VOLUME 119, NUMBER 24
 only.
For personal use at UNIV OF CALIFORNIA DAVIS on July 9, 2012. bloodjournal.hematologylibrary.orgFrom 
anti–T-ALL drug development, the zebrafish (Danio rerio) appears
particularly well-suited because its adaptive immune system is
similar to that of humans,18 T-ALL models have been estab-
lished,19,20 and its use for in vivo drug discovery is advantageous
(reviewed by Langenau et al21).
We have previously shown that dexamethasone, widely used for
treatment of T-ALL, can eliminate immature T cells from the
thymus of zebrafish larvae carrying the T-cell specific p56lck-
promoter:enhanced green fluorescence protein (lck:EGFP) trans-
gene.21 In a novel zebrafish screen we searched a small molecule
library for compounds that similarly eliminate immature T cells
from 5 days post fertilization (dpf) lck:EGFP larvae, reasoning that
active compounds may also eliminate developmentally arrested,
immature T-ALL blasts. One compound we identified, with previ-
ously unknown biologic activity, is active against immature normal
and cMYC-transformed leukemic T cells in adult zebrafish20 and
has selective activity against human leukemia lines. We named the
compound Lenaldekar (LDK; 1H-indole-3-carbaldehyde 8-quinoli-
nylhydrazone). LDK is well tolerated in mice, has favorable
pharmacokinetics, and slows the in vivo growth of human T-ALL
in murine xenografts. Importantly, LDK is active against primary
human leukemia cells, including T315I mutated, BCR-ABL posi-
tive, therapy-refractory B-ALL and CML samples. We show that in
all sensitive cells LDK has 2 independent activities: delay in late
mitosis and inhibition of the P/A/mT pathway, probably by an
indirect route. LDK-resistant cells tested to date lack mitotic delay,
suggesting that both activities of LDK may be required for
cytotoxicity and providing a possible mechanistic basis for its
selectivity. We propose that LDK’s unique activity offers a new,
targeted approach to leukemia treatment.
Methods
Zebrafish and mouse studies
Animal studies were performed according to the University of Utah animal
protocol guidelines under protocol numbers 11-07006 (zebrafish) and
09-11001 and 09-11002 (mouse).
Zebrafish drug screen
The transgenic p56lck:EGFP zebrafish line (lck:EGFP) was previously
described.21 lck:EGFP transgenic zebrafish were bred and eggs collected
and raised in E3 water 5 to 6 dpf. Larvae were then aliquoted 3 per well in a
96-well format in 300 L E3 fish water. Compounds for screening from the
ChemBridge DIVERSet Library (ChemBridge) were added to each well of
the duplicate plates at a final concentration of 10M. Zebrafish larvae were
examined after 2 days of incubation in compounds and scored for thymus
fluorescence via Nikon Eclipse E600 imaging system by 2 operators. Scores
(“unchanged,” “moderate,” or “strong reduction” of fluorescence emitted
from T cells in thymus compared with diluent treated controls) were
compared and reconciled. Initial “hits” were retested and subjected to a
dose-response assay at 1, 5, 10, and 25M. Initially, 112 compounds scored
as “hits.” Of these, 21 compounds that reproducibly caused “strong
reduction” in thymus fluorescence without obvious larval toxicity 10M
were retained for further evaluation.
Zebrafish embryo cell cycle analysis
Dechorionated embryos were incubated with compounds at 4 hours
postfertilization (hpf). At 24 hpf, larvae were dissociated, stained with
propidium iodide (PI), and analyzed for cell cycle status38 using the ModFit
LT Version 3.1 software (Verity Software House).
Leukemic zebrafish experiments
rag2. cMYC-ER zebrafish22 were crossed with lck:EGFP zebrafish and
leukemic adults were identified via fluorescence microscopy for T-ALL
dissemination. Leukemic adults were treated either with vehicle or LDK on
a 2-day-on, 1-day-off treatment regimen with daily water changes. Treat-
ment was discontinued after 14 days. Tumor response was monitored twice
weekly using the Olympus MVX10 Imaging System.
Tissue sections and staining
Fish were fixed in paraformaldehyde (4% in PBS), and sequential 4-micron-
thick sections were either stained with H&E or with anti-GFP antibody
(B-2; Santa Cruz Biotechnology) at 1:400 dilution with hematoxylin
counterstaining.
Mouse xenograft experiments
Male nonobese diabetic (NOD)–severe combined immunodeficiency (SCID)
mice were injected with 500 000 Matrigel (BD Bioscience) embedded
CCRF-CEM-Luc cells per flank. After 3 days, mice were injected intraperi-
toneally twice daily with vehicle only (5% cremophor-EL, 5% N,N-
dimethylacetamide, and 0.7% NaCl in ddH2O at pH 6.0) or LDK
(16 mg/kg) and monitored weekly for tumor progression using Xenogen
IVIS 100 Imaging System (Caliper Life Sciences) and Living Image
Version 2.50 software (Caliper Life Sciences). P values were calculated
using Wilcoxon rank sum test.
Primary human leukemia samples
De-identified primary human patient samples were obtained under the
University of Utah IRB protocol no. 10924. B-ALL samples (see Figure
5A-D) were cocultured with OP9 feeder cells. For CML specimens, frozen
CD34 cells from peripheral blood (PB) of CML-CP (chronic phase)
patients (n  2) were cultured overnight in Iscove modified Dulbecco
medium (IMDM) plus 30% FBS and 2mM L-glutamine supplemented with
IL-3 (20 ng/mL), IL-6 (20 ng/mL), Flt-3 ligand (100 ng/mL), and kit ligand
(100 ng/mL; StemCell Technologies). The CD34 fraction was isolated
using the CD34 MultiSort kit (Miltenyi Biotec). For PhALL specimens,
frozen mononuclear patient cells from PB were cultured overnight in
IMDM plus 30% FBS and 2mM L-glutamine supplemented IL-7 (10 ng/
mL; Peprotech) and treated as indicated.
Results
Zebrafish screen identifies compounds targeted to immature
T cells
Our previous studies revealed that dexamethasone, known for its
toxicity against human lymphoblasts, also eliminates immature
T cells in the thymus of zebrafish larvae.21 We reasoned that among
the molecules identified in a drug screen for their activity against
immature T cells in zebrafish, we would find novel compounds
with the potential to eradicate human T-ALL cells. The use of the
transgenic lck:EGFP line that fluorescently labels all T cells
facilitates rapid assessment of a compound’s effect on T-cell
survival in a 96-well format by fluorescence microscopy.21 Based
on these considerations, 3 lck:EGFP transgenic zebrafish at 5 dpf
were placed in each well of a 96-well plate and incubated for 2 days
with compounds at 10M from the ChemBridge DIVERSet library
(Figure 1A-C). On retesting of 112 primary “hits” (among the
26 400 compounds screened) with strong reduction of EGFP-
positive immature T cells in the thymus of zebrafish larvae, 21 were
retained as candidates (supplemental Table 1, available on the
Blood Web site; see the Supplemental Materials link at the top of
the online article). To ascertain that these “hits,” contrary to
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conventional chemotherapy, did not affect the cell cycle in all cell
types, we incubated each with 20 zebrafish embryos at 4 hours
postfertilization (hpf) and performed cell cycle analysis on cells
isolated from whole embryos at 24 hpf (Figure 1D). Sixteen of the
21 compounds caused detectable cell cycle delays in S-phase or
G0/G1 (supplemental Table 1) and some caused a sub-G1 peak,
indicative of cytotoxicity. The remaining 5 compounds had no
effect on the cell cycle, caused no cytotoxicity (Figure 1E-H) and
thus met criteria for drugs targeted to immature zebrafish T cells.
Lenaldekar induces apoptosis selectively in human leukemic
blasts
Testing these 5 molecules by thiazolyl blue tetrazolium bromide
(MTT) assay in the Jurkat T-ALL line (Figure 2A), one compound
that we named LDK (Figure 2B) was the most potent with an IC50
consistently between 0.8 and 1.3M, measured by both MTT
(Figure 2A,D-F,H) and trypan blue exclusion test (Figure 2C).
LDK was equally effective against the other 4 human T-ALL lines
Figure 1. Zebrafish drug screen identifies anti–T-cell compounds. Zebrafish larvae carrying the T-cell specific lck:EGFP transgene were used for screening of a small
molecule library for anti–T-cell effect. (A) Dorsal (left) and lateral (right) views of 5 days post fertilization (dpf) normal healthy lck:EGFP larva (yellow arrow indicates eye; and
arrowhead, thymus). (B) Three 5-dpf larvae per well in 96-well format were treated with compounds, DMSO (vehicle, yellow box) and dexamethasone (Dex; positive control, red
box). Fluorescence emission was evaluated after 48 hours: no effect/normal fluorescence (dark green), strong effect (light green), toxic effect (black well/red x), and empty well
(hatched). (C) Examples of strong (bottom) and no effect (top). Of 26 400 compounds screened, 387 compounds with weak reduction of thymus fluorescence were also
identified. (D) Twenty-one compounds with strong effect on survival of immature T cells were tested for cell cycle effects in nonlymphoid cells. Four hours postfertilization (hpf)
zebrafish larvae were incubated in candidate compounds for 20 hours, dissociated into single-cell suspensions, stained with propidium iodide (PI) and subjected to flow
cytometry. (E) Representative cell cycle profile for DMSO vehicle-treated embryos. (F) Hydroxyurea-treated embryos show S-phase arrest (arrow) as well as sub-G1 peak
(arrowhead). (G) Lenaldekar (5M) shows a cell cycle profile similar to that of control embryos. (H) Compound 4 shows S-phase arrest (arrow) and sub-G1 peak (arrowhead);
2n indicates G0/G1 phase; 4n, G2/M phase; and between 2n and 4n, S phase. (A-C) Images were acquired at room temperature using Olympus MVX10 microscope with MV
PLAPO 1 lens (Olympus). Camera used was Diagnostic Instruments model 14.2 Color Mosaic Insight FireWire SPOT. Acquisition software used was SPOT Alias Version
4.6 software, 2000 ms exposure with no binning,   1.0. Fluorescence excitation light source was EXFO X-Cite Series 120. (D) Microscope used was Nikon Eclipse E600 with
Nikon Plan APO 4 lens at room temperature. Camera used was CRI Nuance multispectral imaging system model N-MSI-420-FL. SPOT Advanced Version 4.6 acquisition
software was used.
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we tested (Figure 2D). LDK was more potent than GSI IX at
inhibiting growth of 4 primary murine T-ALL lines harboring
mutant NOTCH1, derived from Atm-deficient mice,23 regardless of
PTEN status (supplemental Figure 1). However, the IC50 of LDK in
IL-2 stimulated peripheral blood T cells (PBTCs), B cells, and
monocytes from healthy donors was 10-fold higher than in
lymphoblasts (Figure 2E). AKT is an important enzyme in the
survival of T-ALL cells and developing, immature thymocytes. We
therefore chose an AKT inhibitor to test whether such a molecule
would affect the survival of PBTCs. Interestingly, AKT inhibitor
IV, equipotent to LDK against lymphoblastic cells, readily killed
PBTCs (Figure 2F), which suggests that the lack of LDK activity
against PBTCs was not based on general resistance to cell death in
our assay system, and indicates a superior therapeutic window
compared with a known AKT inhibitor. LDK was active against
3 B-ALL lines with an IC50 of 1 to 2M, but higher concentrations
(IC50 of  25M) were required against the RS4;11 line (Figure
2G). The IC50s of 8 epithelial cancer cell lines tested ranged from
Figure 2. LDK is active against malignant lymphoblasts. IC50 values (M) of indicated treatments by MTT assay after 48-hour incubation are shown in parentheses.
(A) Among 5 hit compounds without general cell cycle effects, only Lenaldekar (LDK) had low micromolar activity against human Jurkat T-ALL (IC50  0.8M). (B) LDK
chemical structure (1H-indole-3-carbaldehyde quinolin-8-yl-hydrazone). (C) Trypan blue exclusion assay for LDK-treated Jurkat cells. (D) LDK dose-response for 5 human
T-ALL lines. (E) LDK dose-response for PBTCs (stimulated with IL-2 30 U/mL), PB B cells (stimulated with IL-10 100 ng/mL), and PB monocytes from healthy human donors,
compared with Jurkat. (F) Dose-response for LDK compared with AKT Inhibitor IV for Jurkat, PBTCs, and PB B cells. (G) LDK dose-response for 4 human B-ALL lines.
(H) Jurkat T-ALL response to LDK in comparison to glioblastoma (U138), melanoma (Lox), and colon cancer (SW480). (A-H) n  3, error bars  SEM.
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20 to 100M, significantly higher than those for lymphoblastic
lines, (Figure 2H, data not shown). To interrogate the apparent
selectivity for lymphoid lineage malignancies, we tested LDK for
efficacy against the NCI60 cell line panel. The 6 hematologic
malignancy lines in this panel, including the multiple myeloma line
RPMI-8226, the AML line HL-60, and the CML-derived line
K-562, had IC50 values of 0.16 to 2.3M, within the range of the
T and B-ALL lines we had previously tested (supplemental Figure
2A). By contrast, the majority of the remaining 54 epithelial cancer
lines had IC50 values more than 10-fold above the hematologic
malignancy lines.
We next explored whether LDK killed Jurkat cells by apoptosis,
the predominant form of cell death after drug treatment. Indeed,
LDK at 1M induced apoptosis in Jurkat cells, measured both by
flow cytometry (supplemental Figure 2B), by Western blot (supple-
mental Figure 2C), and by activated caspase 3 staining (supplemen-
tal Figure 2D). LDK at 10M caused only minimal visible toxicity
in developing zebrafish embryos and larvae (supplemental Table 2).
LDK has in vivo activity in a zebrafish T-ALL model
We next tested whether LDK had anti–T-ALL activity in vivo.
Affected adult individuals from the human cMYC-expressing line
of zebrafish, crossed onto the lck:EGFP background (Figure 3A),
were incubated with LDK at 250nM for 14 days on a 2-days-on/1-
day-off treatment regimen. EGFP emission from T lymphoblasts
was captured by fluorescence microscopy. Eighty-five percent of
treated fish responded to LDK with a marked reduction of
fluorescence extent and intensity (Figure 3B) and the remaining
15% of LDK-treated fish showed stable tumor burden (data not
shown). To ascertain that fluorescence reduction was because of
elimination of T-ALL cells, treated fish were sectioned and
compared with untreated siblings. H&E staining of sections
demonstrated a marked reduction in cells infiltrating nonlymphoid
tissues such as skin and was mirrored by a decrease in EGFP-
positive cells (Figure 3C) in treated individuals. This indicates that
decrease in GFP intensity in LDK-treated zebrafish was because of
absence of T lymphoblasts and not to quenching of the EGFP
signal. By contrast, 100% of vehicle treated fish showed tumor
progression and all succumbed to disease by day 40 (Figure 3B-D).
Remarkably, despite the short course of treatment, the majority of
LDK-treated fish maintained long-term remission (Figure 3D).
LDK is active against human T-ALL in murine xenografts
For in vivo efficacy testing in mammals, we intended to use
luciferase-transduced Jurkat cells, but found that they did not
engraft well into NOD/SCID mice (data not shown), as has been
previously reported.24 We therefore turned to luciferase-transduced
CCRF-CEM T-ALL cells that had IC50 values (Figure 2D) similar
to Jurkat cells, and engrafted better in NOD/SCID mice.24 Other
characteristics of CCRF-CEM cells were also similar to Jurkat cells
(supplemental Figure 6). We embedded 5 105 cells in Matrigel
and transplanted them into each flank of NOD/SCID mice.25 Three
days after xenografting, and then weekly for 4 weeks, mice were
injected with luciferin and luminescence was measured. After the
first measurement, mice were separated into 2 groups, one receiv-
ing diluent only, the other LDK at 16 mg/kg intraperitoneally twice
daily. Luminescence was significantly lower in LDK-treated indi-
viduals on weeks 2, 3, and 4 (Figure 3E-F), resulting in a greater
than 4-fold difference at the end of treatment. Furthermore, the
average weight of the mice in each group was not statistically
different at any time point, indicating lack of gastrointestinal
toxicity of LDK (Figure 3G).
LDK leads to inhibition of the P/A/mT pathway
Next we wanted to identify the biologic pathway modulated by
LDK. Our screening rationale predicted a pathway on which both
immature developing T cells and developmentally arrested, imma-
ture T lymphoblasts are critically dependent. An obvious candidate
is the P/A/mT pathway that is important for survival of immature
T cells.26 In addition, the recent detection of high-frequency
abnormalities in the P/A/mT pathway in T-ALL11 explains their
exquisite sensitivity to inhibition of this pathway.27 Western blot
experiments showed that LDK, but not dexamethasone (data not
shown), led to diminished phosphorylation of AKT on both T308
and S473 (Figure 4A). Similarly, LDK led to dephosphorylation of
mTOR and of p70S6 kinase (S6K), a direct mTOR target (Figure
4B-C). Decreased AKT and mTOR phosphorylation was first
detectable 1 hour after incubation with LDK at 2.5 and 5M,
respectively (supplemental Figure 3A), close to the IC50 in Jurkat
cells. To determine the effects of LDK on AKT’s phosphorylation
dynamics, we examined LDK’s ability to prevent serum-induced
phosphorylation of serum-starved cells. Among T-ALL lines tested,
CCRF-CEM showed the most robust decrease in AKT phosphory-
lation after 72 hours of serum starvation. The known PI3K inhibitor
Ly294002 blocked any rephosphorylation of AKT with a 15- or
30-minute preincubation time (supplemental Figure 3B). LDK, on
the other hand, did not block serum-induced AKT phosphorylation
even after 30 minutes of preincubation and showed reduction of
AKT phosphorylation first at 15 minutes after serum-stimulation
(supplemental Figure 3B). We have also examined phosphorylation
dynamics of S473 and have obtained identical results to T308 (data
not shown).
To test whether P/A/mT pathway inhibition was selective and a
general feature of LDK’s activity in lymphoblastic cells, we
assessed murine B-cell lines Ramos and BaF3 by Phosflow
analysis.28 Growth factor–independent Ramos cells have baseline
hyperphosphorylated SRC and S6 ribosomal protein (S6; supple-
mental Figure 3C). As expected, the tyrosine kinase inhibitor
dasatinib reduced SRC phosphorylation to background levels but
did not affect S6 phosphorylation. Conversely, LDK did not affect
pSRC but reduced S6 phosphorylation close to background levels
(supplemental Figure 3C). The IL-3 dependent pro-B cell line
BaF3 shows increased phosphorylation of signal transducer and
activator of transcription (STAT)3 and S6 after IL-3 stimulation
(supplemental Figure 3D). As expected, JAK Inhibitor I reduced
IL-3–induced phosphorylation of both STAT3 and S6 to back-
ground levels. In contrast, LDK prevented IL-3–induced phosphor-
ylation of S6 but not of STAT3 (supplemental Figure 3D).
Furthermore, LDK did not affect IL-3–induced phosphorylation of
STAT5, ERK1/2, or p38 in BaF3 cells (data not shown). These
findings support selective action of LDK on the P/A/mT signaling
pathway in lymphoblastic lines.
Next we wanted to determine whether inhibition of the P/A/mT
pathway was required for LDK’s cytotoxic activity. For this we
modified a myristoylated form of AKT (myr-AKT, a kind gift from
Dr S. Grant) that targets AKT to the plasma membrane, by
introducing phosphomimetic aspartic acid residues at T308 and
S473. We introduced this constitutively active form of AKT
(myr-AKT-DD) into Jurkat cells. Expression and activity of the
construct was demonstrated by Western blot (supplemental Figure
4A). Whereas native Jurkat cells responded to LDK treatment with
PARP cleavage and marked decrease in viability, constitutively
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Figure 3. LDK treatment inhibits tumor progession in 2 in vivo models of T-ALL. (A-D) Adult rag2:cMYC-ER/lck:EGFP transgenic zebrafish with T-cell leukemia infiltration
(outline) were treated with DMSO vehicle (n  10) or 250nM LDK (n  20) dissolved in E3 fish water over a 2-week period. As continuous exposure to LDK had toxic side
effects, fish were subjected to a well-tolerated 2-day on drug/1-day off drug treatment regimen before being taken off drug altogether after day 14. (A) Fluorescence (left) and
bright field (right) imaging of normal healthy adult rag2:cMYC-ER/lck:EGFP transgenic fish (arrow indicates normal T-cell fluorescence in thymus). (B) Treatment outcome of
leukemic zebrafish incubated in DMSO vehicle only or 250nM LDK. One representative fish shown per treatment. (C) Vehicle control (left panels) and LDK treated (right panels)
leukemic fish were sectioned and stained with H&E (top panels) as well as immunohistochemistry staining for GFP (bottom panels). Scale bars, 10 m. (D) Kaplan-Meier
survival plot shows superior survival of LDK-treated fish. Although all vehicle-treated fish (10/10) had expired by day 40, 67% of LDK-treated fish (13/20) were alive at day
270 (256 days after treatment). Three LDK-treated fish expired of unknown causes. Arrows indicate start and end time points of treatment. (E-G) LDK treatment inhibits tumor
growth in a mouse xenograft model of T-ALL. Thirty male NOD-SCID mice were injected in each flank with 5  105 luciferase-transduced CCRF-CEM T-ALL cells. Cells were
then allowed to engraft for 3 days before first bioluminescence measurement. The mice were then divided into 2 groups of 15 mice each and treated twice daily via
intraperitoneal injection with either LDK (16 mg/kg) or vehicle only. Bioluminescence was assessed weekly with a CCD camera. (E) Representative pictures for tumor
progression in vehicle control (top) versus LDK-treated (bottom) mice. (F) Increase in tumor bioluminescence of vehicle and LDK-treated mice, normalized to baseline.
(*P  .0265, **P  .0006, ***P  .0304). (G) Average weight of LDK-treated (red line) versus vehicle only (blue line) treated mice. Error bars  SEM. (A-B) Images were
acquired at room temperature using the Olympus MVX10 microscope with MV PLAPO 1 lens (Olympus). Camera used was Diagnostic Instruments model 14.2 Color Mosaic
Insight FireWire SPOT. SPOT Alias Version 4.6 acquisition software was used, 2000 ms exposure with no binning,   1.0. Fluorescence excitation light source was EXFO
X-Cite Series 120. (C) Images were obtained using automated immunostainer (BenchMark XT; Ventana Medical Systems) followed by IView DAB detection (Ventana Medical
Systems). (E) Mouse images and tumor emittance data were collected at 37°C using the XENOGEN IVIS 100 imaging system (Caliper Life Sciences) with Spectral Instruments
600 Series camera controller. Mouse images were processed and analyzed for quantitative emittance using Living Image Version 2.50.2 software (Caliper Life Sciences).
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active AKT caused almost complete inhibition of PARP cleavage
and increased LDK’s IC50 3-fold (supplemental Figure 4A-C).
Although these data suggest that inhibition of the P/A/mT pathway
is at least partially required for LDK’s cytotoxic activity in Jurkat
cells it does not address whether LDK’s action on the P/A/mT
pathway is direct or indirect.
To answer this question, we sought to identify enzymes whose
activity LDK may be modulating. Using purified protein substrates
for in vitro kinase assays we tested 33 enzymes, including members
of the P/A/mT pathway and serine/threonine and tyrosine kinases
that may act on the P/A/mT pathway. Whereas the nonspecific
kinase inhibitor staurosporine at 1M potently inhibited the
Figure 4. LDK down-regulates phosphorylation of targets in the PI3K/AKT/mTOR pathway and causes late mitosis arrest in treated cells. (A-C) Jurkat cells were
treated with 10M LDK for the indicated durations then probed for phospho as well as total proteins by Western blot. Densitometric ratio of phospho to total protein is indicated
below the paired panels. (A) LDK treatment reduces phosphorylation of AKT at Thr308 and Ser473. (B) LDK treatment reduces phosphorylation of mTOR. (C) LDK treatment
reduces serum-induced phosphorylation of mTOR downstream target, p70S6 kinase, at 6 hours of treatment. Note that LDK did not prevent serum-induced phosphorylation of
p70S6K at 3 hours. (cropped, noncontiguous sections of same gels are shown for panels A-C). (D-G) Western blot assessment of LDK-treated Jurkat cells indicates that the
G2/M block occurs after anaphase. (D) Schematic of cyclin A and B1 as well as phospho-histone H3 (pH3) temporal expression patterns observed during the mammalian cell
cycle. (E-G) Western blot assessment of LDK (10M) treated cells indicates that neither cyclin A, cyclin B1, nor pH3 accumulate in treated cells. Treatment durations were
24 hours for E and 16 hours for panels F and G. Dox indicates100nM doxorubicin; Noc, 1M nocodazolel; and dox and noc, positive control. (H-I) Western blot assessment of
Jurkat cells treated with the inhibitors doxorubicin and nocodazole indicates that these inhibitors do not cause dephosphorylation of AKT. (E-I) Vinc indicates vinculin loading
control, noncontiguous sections of same gel. Western blots were scanned at room temperature using Epson Expression 1680 scanner and software, 16-bit grayscale
acquisition, 300 dpi resolution. Image processing was done using Adobe Photoshop 9.0.2.
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majority of these enzymes, high doses of LDK (25M) were
required to achieve a mild (20%-30%) reduction in activity of
2 tyrosine and 2 serine/threonine kinases (supplemental Table 3),
and inhibited the remainder of the tested enzymes less than 20%.
To confirm these data we have also tested 451 different kinases,
including lipid and atypical kinase families (KINOMEScan).
Remarkably, LDK at 1M did not inhibit any of the kinases to a
significant degree ( 35% of control activity, data not shown).
Taken together, these data suggest that unlike staurosporine, LDK
is not a nonspecific kinase inhibitor. Rather, it potently induces
inhibition of the P/A/mT pathway in lymphoblasts, probably by
acting on an as of yet unidentified upstream target.
LDK induces cell cycle delay in late mitosis
In most cells, conventional P/A/mT inhibitors, such as wortmannin,
delay the cell cycle in G0/G1 (supplemental Table 4). Surprisingly,
in 4 LDK-sensitive (Ls) lines (Jurkat, CCRF-CEM, 697 and
Nalm-6) LDK induced G2/M delay, whereas the LDK-resistant (Lr)
line RS4;11 was delayed in G0/G1 (supplemental Table 4). A
time-course in Jurkat cells showed that G2/M delay was detectable
by 4 hours after LDK treatment (supplemental Figure 5), and
subsequently cells progressively accumulated in G2/M. To deter-
mine the specific timing of the LDK induced G2/M delay, we
analyzed the expression of cyclin A, cyclin B1, and phospho(Ser10)-
histone H3 (pH3), whose levels are all highly regulated (Figure 4D)
within the mammalian cell cycle.29,30 Whereas the relative expres-
sion of these 3 proteins in Jurkat cells accurately described
doxorubicin-induced G2 delay and nocodazole-induced metaphase
delay, LDK treatment showed a very different profile, indicating an
accumulation of cells in late mitosis (Figure 4E-G).
Taken together our results suggest that LDK has 2 activities in
Ls cells: indirect inhibition of the P/A/mT pathway and cell cycle
delay in late mitosis. We asked whether these 2 activities are
dependent on each other. As P/A/mT inhibition with wortmannin
does not lead to mitosis delay in the T and B-ALL lines we tested
(supplemental Table 4), we probed whether, conversely, G2/M
delay could cause reduced AKT phosphorylation. We induced G2
delay with doxorubicin and mitosis delay using nocodazole.
Neither G2 nor M delay reduced phosphorylation of AKT in Jurkat
cells (Figures 4H-I). We therefore conclude that LDK has
2 independent activities in Ls cells and that inhibition of the
P/A/mT pathway is not a mere consequence of ill health of
LDK-treated cells.
Favorable pharmacokinetics and lack of endorgan toxicity in
LDK-treated mice
We tested serum concentrations of LDK after 14 days of twice daily
intraperitoneal application of LDK at 16, 80, and 200 mg/kg.
Serum concentrations, measured 24 hours after the last intraperito-
neal LDK application, were proportional to the applied doses
(supplemental Figure 7A-B). Determination of pharmacokinetic
properties of LDK in mice revealed a plasma elimination half-life
of  2 hours after both single oral and intravenous administration
(supplemental Figure 7C). In toxicology studies, mice were treated
with LDK by gavage at doses up to 45 mg/kg for 14 days. Mice
remained healthy, did not show weight loss even at the highest
dose, and serum protein, renal, and liver function tests were not
significantly influenced by LDK treatment, regardless of dose (data
not shown). Pathologic examination of kidneys and livers of
diluent and 45 mg/kg LDK-treated animals showed no toxic effects
(supplemental Figure 7D). LDK-treated individuals showed no
significant difference compared with diluent-only treated mice in
PB counts, spleen, and thymus differential cell counts (supplemen-
tal Figure 8A-C). We observed a 10% drop in the percentage of
CD8 single-positive T lymphocytes in the thymus that may be a
reflection of the particular sensitivity of immature, intermediate,
CD8 single-positive thymocytes to AKT inhibition.31 Total num-
bers of thymocytes and overall size of thymi were reduced by
approximately 50% (data not shown).
LDK kills the majority of primary human leukemia cells
To interrogate the clinical relevance of our data, we asked whether
LDK had activity against primary human leukemia samples. We
tested several primary B-ALL samples either grown directly in
culture (supplemental Figure 9, supplemental Table 6) or on OP9
stromal cells (Figure 5A-D, supplemental Table 5) including
treatment-refractory, relapsed BCR-ABL B-ALL and T315I-
mutated BCR-ABL positive B-ALL samples. We found that
proliferation was strongly inhibited in 85% of patient B-ALL
samples and that they exhibited G2/M delay, similar to Jurkat cells
(Figure 5). As the NCI60 data indicated that LDK might have
activity against CML, we also tested 2 primary samples from
patients with imatinib-resistant CML, one with wild-type BCR-
ABL, the other with the T315I mutation. Colony assays demon-
strated strong activity of LDK against both samples, whereas high
doses of imatinib had only mild effects (Figure 5E). Finally, we
tested 3 primary imatinib-resistant Ph B-ALL samples for viabil-
ity in the presence of LDK (Figure 5F). Samples 11-008 and 11-032
are paired diagnosis and relapse samples, with the relapse sample
showing decreased sensitivity to LDK treatment. By contrast, LDK
did not compromise health of normal bone marrow mononuclear
cells at concentrations up to 3M (Figure 5G). Similarly, the IC50
of proliferating human CD34 positive cord blood cells was 8-fold
higher than leukemia cells (Figure 5H), supporting LDK’s therapeu-
tic window we had observed with normal PB mononuclear cells
(Figure 2E). In sum, LDK was active against the majority
of primary human leukemia samples, and led to G2/M delay
in Ls cells.
Discussion
The screen described herein represents the first successful and
unbiased approach using zebrafish larvae to identify molecules
with potency against a human cancer from a small molecule library
containing compounds with unknown activity. Zebrafish have been
increasingly used to screen for bioactive compounds with possible
clinical relevance. For example, a screen of 2000 well-character-
ized compounds (Spectrum Library, MicroSource Discovery Sys-
tem) revealed PGE2 as a stimulator of hematopoietic stem cell
growth,32 a finding that is now being translated into clinical trials
(L. Zon, personal e-mail communication, December 13, 2011). In
another screen of the Spectrum Library for active compounds in a
zebrafish model of acute myeloid leukemia (AML), Yeh et al
identified a new role for COX-2 and 	-catenin in AML1-ETO–
induced AML.33 More recently, a screen of the Spectrum Library
for chemical suppressors of neural crest development revealed a
class of dihydroorotate dehydrogenase inhibitors that not only
almost completely abrogate neural crest development in zebrafish
but also markedly decrease melanoma growth both in vitro and in
mouse xenograft studies.34
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Drug screening in zebrafish offers the obvious advantage of
being conducted within the context of an entire vertebrate organ-
ism, including intact, heterologous cell-cell interactions (eg, thymo-
cyte-thymic epithelial cells or hematopoietic stem cell–stromal
cells). As our results demonstrate, such a screen can identify
relatively nontoxic compounds with selective bioactivity in human
cells. However, there are also clear limitations in how far we can
extrapolate results from zebrafish drug screening to mammals. For
example, zebrafish screens may have relevance for bioavailability
as demonstrated by LDK. However, there are 3 routes of absorption
Figure 5. LDK is active against primary patient samples without toxicity to hematopoietic progenitors. (A-D) LDK decreases viability and induces G2/M block in primary
Ph B-ALL patient samples. Left side of each panel shows MTT test of LDK dose-response viability assay at 48 hours incubation, n  3, error bars  SD. Right side of each
panel shows cell cycle profile for primary patient samples treated for 12 hours with DMSO, 10M LDK, and 3M nocodazole, n values as indicated, error bars  SEM.
(E-H) LDK decreases viability of Ph CML and B-ALL primary leukemias without toxicity to hematopoietic stem/progenitor cells (HSPCs). (E) Cytokine-dependent
methylcellulose colony formation (mean 
 SD) of CML-CP (CP indicates chronic phase) with wild-type BCR-ABL (patient ID no. 10-003, black bars) and T315I mutated
BCR-ABL (patient ID no. 11-007, gray bars), either untreated or treated with the indicated inhibitors. (F) Trypan blue viability assay of mononuclear cells from 3 Ph B-ALL
patient samples treated with the indicated inhibitors. Samples 11-008 and 11-032 are paired samples from the same patient at diagnosis and relapse, respectively.
(G) Cytokine-dependent methylcellulose colony formation (mean 
 SD) of normal bone marrow mononuclear cells, treated with either DMSO or LDK at the indicated
concentrations. (H) MTT viability assay of CD34 HSPCs from human cord blood, treated with LDK at the indicated concentrations, relative to vehicle control. Error bars  SD
Additional primary patient sample characteristics may be found in supplemental Table 5.
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in fishes after immersion in compound (gastrointestinal, gill, and
skin), compared with only one after oral application in mammals,
and only the gill route is not available in zebrafish larvae at 5 dpf
when we carried out the screen. In addition, the exposure to drug is
constant and only restricted by stability in water during immersion,
a different scenario from the intermittent oral dosing in mammals.
Therefore, bioavailability in fishes may not accurately predict the
same in mammals. Finally, targets may have diverged during
evolution so that compounds that are active in zebrafish may not
exhibit the desired effect in mammalian cells. This may be the case
for the 4 compounds that had specific activity in zebrafish but did
not kill Jurkat cells in our screen (Figure 2A).
Screening of large numbers of compounds is not practical in
adult leukemic zebrafish. However, contrary to the AML model,35
currently no zebrafish T-ALL models exist that manifest early in
development to allow screening of thousands of compounds. We
developed a 2-pronged screening strategy to identify targeted,
nontoxic, antileukemia compounds in zebrafish larvae from a large
chemical library. First, we reasoned that given their similar
developmental stage, immature T cells and leukemic T lympho-
blasts share similar pathways or biologic processes on which both
critically depend. Consequently, compounds that eliminate the
former may also kill the latter. Our rationale was supported by our
previous finding that dexamethasone, a mainstay of anti-ALL
treatment, eliminated immature T cells from the thymus of
developing zebrafish larvae.21 Our data that killing of immature
zebrafish T cells and malignant human T-ALL lines by LDK
involves indirect inhibition of the P/A/mT pathway (see below)
bolstered our rationale as both types of cells critically depend on
AKT activity for survival.14,26,36 Second, we sought to identify
active molecules that are devoid of general toxicity. The capacity to
interfere with the cell cycle of dividing cells underpins the efficacy
and toxicity of most chemotherapeutic agents. Despite species-
specific variations, cell cycle regulation is highly conserved
throughout metazoan evolution37 and modulators of the cell cycle
identified in zebrafish are active in mammals and vice versa.38,39
We therefore reasoned that nontargeted compounds that are gener-
ally toxic to mammalian cells could be detected and eliminated by
screening for cell cycle effects in developing zebrafish embryos
(Figure 1D-H). Our finding that LDK has little toxicity in
developing and adult zebrafish, mice, and nonmalignant human
cells corroborates the rationale for our screening algorithm.
The P/A/mT pathway has become an attractive target for drug
development16 and molecules have been identified that inhibit 140,41
or 227,42,43 components of the pathway. The targets of these
inhibitors are either the 3 enzymes themselves or kinases that
activate the pathway, as for example PDK144 and mTORC2.45
These inhibitors act against a wide range of tumor cell lines that
depend on P/A/mT signaling.46 LDK induces decreased phosphor-
ylation state in members of the P/A/mT pathway and has potent
activity against leukemias. Several lines of evidence indicate
that LDK exerts an indirect effect on the P/A/mT pathway. First,
extensive in vitro kinase assays clearly show that LDK does not
significantly inhibit any of the members of the P/A/mT pathway.
Second, in our serum starvation experiments, LDK exhibited markedly
delayed activity on AKT phosphorylation compared with the PI3K
inhibitor Ly294002. Third, LDK lacks activity against several AKT-
dependent tumor lines, including glioblastoma and melanoma that are
readily killed by AKT inhibitors. We therefore conclude that LDK’s
action on the P/A/mT pathway is indirect.
What is the underpinning of LDK’s leukemia selectivity?
Although the molecular basis of LDK resistance versus sensitivity
remains the subject of future investigations, selective antileukemia
activity could be explained by several mechanisms. These include a
hematopoietic cell-restricted target (Figure 2, supplemental Figure
2), unique sensitivity of lymphocytes47 to LDK’s action, or
differential drug metabolism by resistant versus sensitive lines.48
Finally, the 2 activities of LDK may have to coincide for
cytotoxicity. For example, hematopoietic cells can overcome cell
cycle arrest in G2/M through growth factor-stimulated activation of
the P/A/mT pathway.49 Thus, LDK’s ability to induce G2/M delay
while simultaneously blocking the P/A/mT pathway, even after
growth factor stimulation (supplemental Figure 3D), appears
particularly significant. A requirement for dual activity is bolstered
by our observation that in RS4;11 cells failure of LDK-mediated
G2/M delay correlates with resistance (Figure 2G, supplemental
Table 4). We have shown that LDK’s 2 activities, P/A/mT
inhibition and late mitosis delay, are independent of each other
(Figure 4H-I), but whether LDK accomplishes selectivity by
interfering with single or multiple targets must be addressed in
future studies.
In our study, LDK was active as monotherapy against all T-ALL
lines tested and 85% of primary leukemia samples, regardless of
PTEN status, resistance to glucocorticoids or other antileukemia
compounds that may compromise patient treatment. Furthermore,
with our dosing regimen LDK lacks endorgan (supplemental
Figure 7D) and hematopoietic toxicity (Figures 2E and 5G-H,
supplemental Figure 8). Thus LDK is an attractive, nontoxic
compound that will form the basis of future endeavors to bring
leukemia-selective treatments to the bedside.
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